Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 12Thoracic 6Other hematologic neoplasm 4Gastrointestinal 4Myeloid 3Lymphoid 3Gynecologic 3Dermatologic 3CNS 3Sarcoma 2Head & Neck 2Tumor-Agnostic 1Plasma cell 1Genitourinary 1Endocrine 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hodgkin Disease 1Chemotherapy-Related Cognitive Impairment 1Breast Neoplasms 1

Interventions

Rituximab 530Cyclophosphamide 425Vincristine 219Doxorubicin 192fludarabine phosphate 177Etoposide 167Prednisone 166fludarabine 162Methotrexate 162Cytarabine 157Filgrastim 125Dexamethasone 123Lenalidomide 121Granulocyte Colony-Stimulating Factor 116Whole-Body Irradiation 107Mycophenolic Acid 99ibrutinib 97Bendamustine Hydrochloride 91Tacrolimus 88Melphalan 85Calcium Dobesilate 82Peripheral Blood Stem Cell Transplantation 80Bortezomib 80Busulfan 78obinutuzumab 64ofatumumab 59Radiotherapy 57Cyclosporine 57Antilymphocyte Serum 55Brentuximab Vedotin 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Sodium Chloride × Lymphoid × Clear all
NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

NCT04095858 2023-02-08

CATHY

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3 Terminated
11 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01205503 2016-02-24

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

University of Kentucky

Phase 2 Completed
32 enrolled 24 charts
BreastLymphoid

Chemotherapy-Related Cognitive Impairment, Breast Neoplasms, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡